» Articles » PMID: 16997354

Direct and Indirect Evidence for the Reversibility of Cirrhosis

Overview
Journal Hum Pathol
Specialty Pathology
Date 2006 Sep 26
PMID 16997354
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to assess the reversibility of cirrhosis after therapy in a large series of patients with cirrhosis from various etiologies. We performed a retrospective study of 113 patients with biopsy-proven cirrhosis who underwent specific therapy and follow-up biopsies. Two pathologists performed blinded analyses of indirect biochemical and morphological signs of cirrhosis. Fourteen (12.4%) of the 113 cirrhotic patients had biopsy-proven disappearance of cirrhosis, defined as a decrease of 2 or greater in their METAVIR fibrosis score: 8 were related to hepatitis C virus, 3 to hepatitis B virus, and 3 to autoimmune cirrhosis. Necro-inflammatory activity decreased from 2.4 +/- 0.65 to 0.85 +/- 0.9 (P = .004), and fibrosis from 4 to 1.7 +/- 0.61 (P = .001). Prothrombin time (n = 1), platelet count (n = 2), serum albumin level (n = 2), and ultrasound abnormalities (n = 6) normalized in patients who had initial abnormalities. Hyaluronic acid and procollagen type III serum level decreased in all. In the 11 patients with regression of viral cirrhosis, 2 were nonresponders and 9 were responders, including 2 relapsers. The 3 patients with regressive autoimmune cirrhosis were complete responders to immunosupressive therapy. Using repeated liver biopsies, clinicobiochemical, radiologic, and endoscopic tests, we provide evidence for potential reversibility of cirrhosis after long-lasting suppression of the necro-inflammatory activity of liver disease.

Citing Articles

The strategy of laparoscopic surgery for asymptomatic antenatally diagnosed choledochal cyst.

Zhang X, Jin J, Qiu T, Zhou J, Che G, Ji Y BMC Surg. 2023; 23(1):204.

PMID: 37464354 PMC: 10354969. DOI: 10.1186/s12893-023-02095-3.


Texture Analysis of Gray-Scale Ultrasound Images for Staging of Hepatic Fibrosis.

Park E, Kim S, Park S, Baek T Taehan Yongsang Uihakhoe Chi. 2022; 82(1):116-127.

PMID: 36237456 PMC: 9432409. DOI: 10.3348/jksr.2019.0185.


Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.

Orr C, Wang P, Chen L, Wang T PLoS One. 2022; 17(5):e0267474.

PMID: 35552548 PMC: 9098014. DOI: 10.1371/journal.pone.0267474.


Liver fibrosis quantification.

Venkatesh S, Torbenson M Abdom Radiol (NY). 2022; 47(3):1032-1052.

PMID: 35022806 PMC: 9538706. DOI: 10.1007/s00261-021-03396-y.


Liver fibrosis assessment: MR and US elastography.

Ozturk A, Olson M, Samir A, Venkatesh S Abdom Radiol (NY). 2021; 47(9):3037-3050.

PMID: 34687329 PMC: 9033887. DOI: 10.1007/s00261-021-03269-4.